UK 22:07 Wednesday, 23 September 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Previously writing on Polarean Imaging (POLX), in September with the shares down to 11.5p and it emphasising it having “successfully developed the first and only hyperpolarised MRI contrast agent to be approved in the United States”, I warned it’s the balance sheet which soon needed to be revolutionised and, considering the funding environment and a down to below £25 million market cap, it was good luck with such fundraising! Natch, avoid/sell. The shares most recently closed at 3.7p and now CEO Christopher von Jako is “delighted to announce today's successful placing and subscription of $10 million”. Er, why are the shares currently at 1.3p then, a further 65% down?!
Already a member? Sign in
• All premium articles
• Tom Winnifrith’s Bearcast
• Access to all the entire nearly 13 year archive
• ShareProphets Daily Newsletter
Cancel any time
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
